Search
Filter by category
Filter by category
Filter by category
Filter by category
Filter by content type
Filter by form group
Filter by type
Filter by tags
Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants
January 15, 2026 - … and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN … and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN … and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population SOUTH SAN …
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
March 5, 2025 - … demonstrating statistically significant increases in serum anti-VP1 IgA compared to the placebo cohort on day 29 and day … in vaccine-induced responses were also observed for serum anti-VP1 IgG in all vaccinated cohorts on day 29 and day 57 … demonstrating statistically significant increases in serum anti-VP1 IgA compared to the placebo cohort on day 29 and day …
Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia
August 28, 2024 - … needed to further characterize the immune stimulating and anti-tumor activity of our HPV-vaccine, these initial … compared to control groups. Concurrent administration of anti-PD-1 with vaccination further increased animal survival … needed to further characterize the immune stimulating and anti-tumor activity of our HPV-vaccine, these initial …
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
September 6, 2023 - … Significant increase in the induction of HBGA blocking anti-bodies in the vaccinated cohort (GMFR 3.23) compared … Significant increase in the induction of HBGA blocking anti-bodies in the vaccinated cohort (GMFR 3.23) compared … Significant increase in the induction of HBGA blocking anti-bodies in the vaccinated cohort (GMFR 3.23) compared …
Vaxart Announces Creation of Manufacturing and Quality Advisory Board
September 21, 2021 - … for consolidating all phases of drug development for anti-infective drugs in the U.S. and worldwide. Siporin also … for consolidating all phases of drug development for anti-infective drugs in the U.S. and worldwide. Siporin also … for consolidating all phases of drug development for anti-infective drugs in the U.S. and worldwide. Siporin also …
Vaxart Reports Boosting Immune Responses in Subjects Previously Vaccinated by a Vaxart Vaccine
July 29, 2021 - … the viral vector as well as the intended antigens. "Anti-vector antibodies from the injected vaccine immune … the viral vector as well as the intended antigens. "Anti-vector antibodies from the injected vaccine immune … the viral vector as well as the intended antigens. "Anti-vector antibodies from the injected vaccine immune …
Vaxart Announces Additional Preclinical COVID-19 Oral Vaccine Data and Publication
January 26, 2021 - … N protein was included because it would generate specific anti-viral T-cell responses against a more conserved protein … N protein was included because it would generate specific anti-viral T-cell responses against a more conserved protein … N protein was included because it would generate specific anti-viral T-cell responses against a more conserved protein …
Vaxart Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 12, 2020 - … the Company’s lead vaccine candidates generated robust anti-SARS CoV-2 antibodies in all tested animals after both … the Company’s lead vaccine candidates generated robust anti-SARS CoV-2 antibodies in all tested animals after both … the Company’s lead vaccine candidates generated robust anti-SARS CoV-2 antibodies in all tested animals after both …
Vaxart Announces Corporate Update for First Quarter 2020
April 28, 2020 - … announced that its lead vaccine candidates generated anti-SARS CoV-2 antibodies in all tested animals after the … announced that its lead vaccine candidates generated anti-SARS CoV-2 antibodies in all tested animals after the … announced that its lead vaccine candidates generated anti-SARS CoV-2 antibodies in all tested animals after the …
Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program
April 21, 2020 - … April 21, 2020 General Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First … animals that received one of the Vaxart vaccines had IgG anti-SARS CoV-2 antibodies in serum two weeks after the first … Source: Vaxart, Inc. Lead Vaccine Candidates Generate Anti-SARS CoV-2 Antibodies in All Tested Animals after First …